Affymax (AFFY) Trades Higher Following $5M Milestone Payment from Takeda
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Affymax, Inc. (Nasdaq: AFFY) seeing a little break above the $10.60 price level Monday. shares are up nearly 3 percent on the session following receipt of a $5 million milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.
According to the release: "The milestone is triggered by the European Medicines Agency (EMA) acceptance of the Marketing Authorization Application (MAA) for the investigational compound peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis."
According to the release: "The milestone is triggered by the European Medicines Agency (EMA) acceptance of the Marketing Authorization Application (MAA) for the investigational compound peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis."
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
